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Tumor blood vessels deliver oxygen poorly, thereby contributing to tumor hypoxia and upregula-
tion of proangiogenic cytokines in an escalating feedback loop. Mazzone et al. (2009) now show 
that reducing the amount of a protein involved in endothelial oxygen sensing leads to changes in 
endothelial cell shape that interrupt this feedback loop and reduce tumor metastasis.There is a paradox in tumor biology that 
only became obvious when antiangio-
genic drugs became available for testing 
in animal models and clinical trials. Most 
tumors require their own blood supply 
to grow, and once a tumor has made 
the “angiogenic switch,” it is capable of 
inducing blood vessel formation to sup-
ply its metabolic needs (Hanahan and 
Folkman, 1996). Although it was thought 
that compounds that block tumor 
angiogenesis would be effective in can-
cer therapy, to date the available drugs 
only transiently block tumor growth. 
There are likely numerous reasons for 
this outcome (Bergers and Hanahan, 
2008), but one interesting possibility 
centers around the peculiar character-
istics of tumor-induced blood vessels. 
Tumor blood vessels are leaky and inef-
ficient at oxygen delivery. As a result, 
the tumor remains oxygen starved, or 
hypoxic. Hypoxia stimulates tumor cells 
to continue production of cytokines and 
growth factors, including proangiogenic 
factors that over-stimulate tumor blood 
vessels and keep them dysfunctional. 
It has been proposed that “normaliz-
ing” blood vessels to better perfuse the 
tumor tissue may actually downregu-
late the signaling pathways that con-
tribute to tumor growth (Jain, 2005). In 
this issue, Mazzone et al. (2009) show 
that perturbing the oxygen-sensing 
pathways of endothelial cells leads to 
normalization of tumor blood vessels. 
Moreover, this endothelial normalization 
dramatically blocks tumor invasion and 810 Cell 136, March 6, 2009 ©2009 Elseviermetastasis, suggesting that endothelial 
oxygen sensing may be a compelling 
target for cancer therapy.
The study focuses on a component 
of cellular oxygen sensing called pro-
lyl hyroxylase domain protein 2 (PHD2). 
PHD2 is one of a group of proteins that 
hydroxylate critical residues in subunits of 
hypoxia-inducible factors (HIFs), a modifi-
cation that targets the HIFs for degrada-
tion (Semenza, 2003). When oxygen ten-
sion is normal, HIF degradation prevents 
the activation of downstream targets in 
the hypoxic response. To activate the 
hypoxic response, PHD activity is down-
regulated and HIF subunits are stabilized. 
Mazzone et al. genetically deleted PHD2 
and found that complete loss of PHD2 is 
embryonic lethal, consistent with previ-
ous findings (see for example Takeda et 
al., 2006). Thus, the authors focused on 
the effects of heterozygosity for PHD2 
(PHD2+/−). PHD2+/− mice express PHD2 at 
50% of wild-type levels and have normal 
blood vessel parameters under physiolog-
ical conditions. They then used xenografts 
to produce wild-type tumors that contain 
blood vessels with reduced amounts of 
PHD2. They hypothesized that reduction 
of endothelial PHD2 via heterozygosity 
would lead to increased tumor invasion and 
metastasis due to hypoxia-driven upregu-
lation of signaling pathways. Instead, 
they found the opposite result—tumors 
with blood vessels that expressed less 
PHD2 were better perfused, less invasive, 
and much less metastatic than the same 
tumors with wild-type blood vessels. Inc.The authors go on to show that tumor 
blood vessels with reduced PHD2 are 
as abundant as wild-type tumor blood 
vessels, but the blood vessels express-
ing less PHD2 resemble normal, non-
tumor blood vessels. They are less 
leaky, have better pericyte coverage, 
and have a more consistent basement 
membrane—all hallmarks of mature, 
quiescent vessels. However, the most 
salient differences between wild-type 
and PHD2-reduced tumor blood ves-
sels pertain to their physical appear-
ance and expression profile. Scanning 
electron micrographs of the inner blood 
vessel wall showed that endothelial 
cells of wild-type tumor blood vessels 
were disorganized, with cells inside the 
lumen and gaps between the cells. In 
contrast, the endothelial cells of blood 
vessels with reduced PHD2 had a uni-
form shape that produced an even 
and smooth lining with no gaps. The 
authors termed this uniformity a “pha-
lanx” phenotype (a phalanx is a seam-
less formation of soldiers along a battle 
line, in military parlance). Conditional 
heterozygosity for PHD2 in endothelial 
cells recapitulates these effects, indi-
cating that vessel normalization is initi-
ated by endothelial cells.
How might changes in a cell’s oxy-
gen-sensing machinery set into motion 
events leading to vessel quiescence and 
normalization? The gene expression pro-
file of freshly isolated endothelial cells 
shows that both isoforms of the vascular 
endothelial growth factor receptor Flt1 
Figure 1. Reduction of PHD2 Inhibits Metastasis
Tumor environments are hypoxic, which leads to upregulation of cytokines such as vascular endothelial growth factor (VEGF) that over-stimulate entering blood 
vessels. In endothelial cells, downregulation of prolyl hydroxylase domain proteins (PHDs) leads to upregulation of hypoxia-inducible factors (HIFs). However, 
the stimulation of downstream effectors of HIFs, including vascular endothelial cadherin (VE-cadherin) and soluble Flt1 (sFlt1), is insufficient to overcome 
cytokine stimulation. Blood vessels are leaky, open to invasive metastatic tumor cells, and deliver oxygen poorly. This leads to escalating tumor hypoxia. 
Tumors vascularized with blood vessels that express reduced PHD2, however, are less hypoxic and invasive. This results from a normalization of blood vessel 
morphology, in which endothelial cells adopt a “phalanx” phenotype characterized by smooth nonleaky blood vessels that effectively deliver oxygen and block 
metastasis. Increased expression of sFlt1 (a negative regulator of VEGF signaling) and VE-cadherin (which stabilizes junctions) are thought to contribute to the 
quiescent, normalized endothelial phenotype.(VEGFR-1) and the junction protein vas-
cular endothelial-cadherin (VE-cadherin) 
are markedly upregulated. This finding 
suggested that these proteins could be 
downstream effectors of oxygen-depen-
dent vessel normalization. The soluble 
Flt1 (sFlt1) isoform is a negative regulator 
of VEGF signaling (Kendall and Thomas, 
1993), and VE-cadherin is found in junc-
tions but is also a critical regulatory node 
for junction assembly and endothelial 
barrier function (Taddei et al., 2008). The 
link to oxygen sensing is strengthened 
by experiments showing that HIF-2α reg-
ulates expression of both potential effec-
tors. Indeed, in cell culture, knockdown 
of HIF-2α is more effective than knock-
down of HIF-1α in reducing expression 
of both VE-cadherin and sFlt1. More-
over, HIF-2α protein is localized to tumor 
vessels. Other groups have shown that 
both VE-cadherin and Flt1 have hypoxia-
response elements in their promoters 
that are recognized by HIF-2α (Dutta et 
al., 2008; Le Bras et al., 2007).
Thus, a model emerges for how the 
hypoxic response may differentially affect 
tumor cells and endothelial cells and how this might lead to the surprising finding 
that reduction of PHD2 activity in endothe-
lial cells blocks tumor invasion and metas-
tasis (Figure 1). In a hypoxic tumor environ-
ment, entering blood vessels downregulate 
PHDs and upregulate HIFs. In endothelial 
cells, HIF-2α is sensitive to PHD2 levels, 
and a reduction of PHD2 to half of nor-
mal levels allows downstream effectors 
of HIF-2α, such as sFlt1 and VE-cadherin, 
to overcome the influx of tumor-derived 
hypoxia signals that induce dysfunctional 
blood vessels. The PHD-deficient blood 
vessels form a “phalanx” phenotype that 
improves oxygen delivery, reduces tumor 
hypoxia, and blocks intravasation of inva-
sive and metastatic tumor cells into the 
blood vessels. In contrast, wild-type blood 
vessels have more PHD2 and less HIF-2α, 
VE-cadherin, and sFlt1. Thus, they cannot 
overcome the influx of tumor signals and 
remain leaky and open to invasive tumor 
cells. Moreover, these wild-type blood 
vessels do not improve oxygen delivery 
and so cannot break the cycle of signaling 
induced by the hypoxic response of tumor 
cells. This may lead to an escalating feed-
back loop.Cell 1There are numerous interesting 
questions provoked by these findings 
and this model. It will be important to 
show that these findings are relevant 
in spontaneous tumors that closely 
mimic tumors seen in the clinic. It will 
also be exciting to see how other signal-
ing pathways that affect angiogenesis 
and vessel morphology intersect with 
this regulatory module. For example, 
platelet-derived growth factor (PDGF) 
signaling and signaling of angiopoietin 
through Tie receptors can also promote 
vessel quiescence. The role of other 
components of the oxygen-sensing 
pathway in blood vessel normalization 
requires further clarification, especially 
given that HIF-1α regulates a gene set 
that does not completely overlap with 
the set regulated by HIF-2α.
The work of Mazzone et al. is sig-
nificant in several ways. The data high-
light that the endothelial cell’s ability to 
sense oxygen has an important impact 
on blood vessel morphogenesis and 
function. The description of the “pha-
lanx,” a new endothelial phenotype 
that is oxygen sensitive, underscores 36, March 6, 2009 ©2009 Elsevier Inc. 811
the notion that phenotypic heterogene-
ity of endothelial cells within blood ves-
sels is critical to proper development 
and function. The work provides an 
example of how changes to cell shape 
rather than cell numbers dramatically 
affects blood vessel phenotype and 
tumor progression. Finally, blood ves-
sel normalization affects tumor inva-
sion and metastasis, suggesting that 
endothelial oxygen sensing may repre-
sent a new target of cancer therapy.812 Cell 136, March 6, 2009 ©2009 Elsevier
Most cells spend a large portion of the 
cell cycle preparing to replicate their 
DNA. Replication initiates from regions 
in the chromosomal DNA called repli-
cation origins in a process referred to 
as origin firing. These origins attract the 
six origin recognition complex (ORC) 
proteins during mitosis. The binding 
of ORC proteins to the origin serves to 
initiate a multistaged process involving 
the recruitment of a series of different 
proteins that results in the separation 
of the two DNA strands, loading of the 
DNA polymerase, and initiation of DNA 
replication (Figure 1). Yet, virtually noth-
ing is known about the mechanisms by 
which these regions, crucial to replica-
tion, are selected and when this selec-
tion is made. Furthermore, unlike in 
prokaryotes, in eukaryotes there are no 
known characteristics that can help to 
predict whether a given DNA sequence 
can serve as an origin of DNA replica-
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